Initiation of an emergency department discharge pathway for low-risk patients with venous thromboembolism: Factors impact real-world practice - Summary - MDSpire
Advertisement
Initiation of an emergency department discharge pathway for low-risk patients with venous thromboembolism: Factors impact real-world practice
To evaluate the effect of a discharge pathway for low-risk VTE patients on patient outcomes in the emergency department.
Approach:
Study Design: A retrospective cohort study of 1260 patients with VTE diagnosed in the ED, comparing data from two years before and after the implementation of a discharge pathway.
Pathway Implementation: The pathway included an outpatient VTE guidance document, scheduling follow-ups, and DOAC prescriptions facilitated by clinical pharmacists.
Data Collection: Patient demographics, medical history, labs, medications, and outcomes were extracted using an NLP algorithm and various coding systems.
Key Findings:
The incidence of VTE has increased significantly in the US and Europe over the last two decades.
Only 1 in 13 eligible patients with PE are treated at home, indicating a gap in outpatient management.
Approximately 30-50% of patients with PE may be low risk and suitable for discharge.
Interpretation:
The study evaluates the implementation of a discharge protocol for low-risk VTE patients.
Limitations:
Individual pathway use could not be measured retrospectively, which limits understanding of its practical application.
The study was not designed as a formal quality improvement intervention.
Conclusion:
The implementation of a discharge protocol for low-risk VTE patients may enhance outpatient management.
by William B Stubblefield, James Barclay, Jesse O Wrenn, Doug Conway, Scott Nelson, Quinn S Wells, Dario Giuse, Zhao Zuo, Alexandra M Baird, Tyler Barrett, Shi Huang, Karen Beauchamp, Alan B Storrow, Sean P Collins, Joshua A Beckman
Narrative review describes how physiologic stressors accumulate from induction through postintubation care and may contribute to cardiovascular deterioration during airway management.
First Treg-based cell therapy approved, FDA advanced therapy office faces fresh turnover, and preclinical CAR T studies target rare blood cancers and glioblastoma
